Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic ...

New Afrezza prescribing information outlines higher starting dose conversions for patients transitioning from mealtime ...

The FDA has approved a label update for an inhaled insulin indicated for adults with type 1 or type 2 diabetes, according to ...

Results from a new study suggest a combination of the diabetes drug Ozempic and an innovative new intestinal procedure could help erase the need for insulin in folks with Type 2 diabetes. Photo by ...

For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation ...

MADRID — The de-escalation of a multiple daily injection regimen of insulin for type 2 diabetes to a once-daily fixed-ratio combination of insulin glargine U100 and glucagon-like peptide 1 receptor ...

A clinical trial has shown that Ozempic improves blood glucose levels and weight loss in overweight type 1 diabetics who use an automated insulin delivery system. It’s hoped that this will lead to the ...

Dr Anne Peters of the Keck School of Medicine of the University of Southern California reports on the latest research on insulin therapy in adults with type 2 diabetes (T2D), presented at the 2023 ...

Insulin-producing cells can be genetically modified to hide from the immune system. People with type 1 diabetes must constantly rely on insulin injections or pumps, usually for the rest of their life ...

A comprehensive study presented at the Endocrine Society’s ENDO 24 annual meeting has revolutionized understanding of diabetes management during pregnancy. Following 10,117 mother-child pairs for up ...

Please provide your email address to receive an email when new articles are posted on . The proportion of large for gestational age infants was higher with oral agents vs. insulin therapy for women ...

By Dr. Liji Thomas, MD Fear of insulin cognitive overload and workplace constraints can derail gestational diabetes care, but ...